CM
PTLA

Crestline Management’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Crestline Management’s Portfolio PTLA Stock Details PTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-13,564
Closed -$512K – 267
2018
Q2 		$512K Buy
+13,564
New +$519K 0.05% 221
2017
Q3 		– Sell
-18,305
Closed -$1.03M – 192
2017
Q2 		$1.03M Buy
+18,305
New +$733K 0.14% 88

Other funds holding PTLA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Crestline Management's PTLA Position: Q3 2018 in Review

Crestline Management sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q3 2018, closing a stake of 13,564 shares — an estimated $512K sold.

Crestline Management first reported a position in PTLA in Q2 2017 and held it in 2 quarters. The position peaked at $1.03M in Q2 2017. 197 funds tracked by Wall St. Rank hold PTLA as of Q3 2018.

  • Crestline Management reported no remaining Portola Pharmaceuticals, Inc. position as of Q3 2018 after selling out during the quarter.
  • Crestline Management sold 13,564 Portola Pharmaceuticals, Inc. shares in Q3 2018, an estimated $512K.
  • Crestline Management first reported a position in Portola Pharmaceuticals, Inc. in Q2 2017 and held it in 2 quarters.
  • Crestline Management's Portola Pharmaceuticals, Inc. position peaked at $1.03M in Q2 2017.
  • 197 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q3 2018.

Based on Crestline Management's 13F filing for Q3 2018, filed 14 Nov 2018.